Last reviewed · How we verify

Bupivacaine-Dexamethasone

SEBASTIAN ROCHE · FDA-approved active Small molecule Quality 2/100

Bupivacaine-Dexamethasone is a Small molecule drug developed by SEBASTIAN ROCHE. It is currently FDA-approved.

Bupivacaine-Dexamethasone, marketed by Sebastian Roche, is a combination drug currently available in the market with a key composition patent expiring in 2028. The drug's key strength lies in its unique mechanism of combining bupivacaine and dexamethasone, potentially offering enhanced efficacy and duration of action compared to monotherapy options. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.

At a glance

Generic nameBupivacaine-Dexamethasone
SponsorSEBASTIAN ROCHE
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine-Dexamethasone

What is Bupivacaine-Dexamethasone?

Bupivacaine-Dexamethasone is a Small molecule drug developed by SEBASTIAN ROCHE.

Who makes Bupivacaine-Dexamethasone?

Bupivacaine-Dexamethasone is developed and marketed by SEBASTIAN ROCHE (see full SEBASTIAN ROCHE pipeline at /company/sebastian-roche).

What development phase is Bupivacaine-Dexamethasone in?

Bupivacaine-Dexamethasone is FDA-approved (marketed).

Related